Surf Bio

News

Halozyme has expanded its portfolio of drug delivery technologies for a second time in a few months with the acquisition of Surf Bio for up to $400m.

News

BioNTech's vaccine for head and neck cancer has failed a clinical trial, but it will wait for more data before deciding the programme's fate.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.